Paper Details
- Home
- Paper Details
Biological and radiological responses to oral etidronate and tiludronate in Paget's disease of bone.
Author: DevogelaerJ P, MalghemJ, Nagant de DeuxchaisnesC, StasseP
Original Abstract of the Article :
Paget's disease of bone is characterized by a high bone turnover. Therefore, antiresorbing agents such as bisphosphonates are clearly indicated. However, as they accumulate in the pagetic lesions, they could produce some focal defects of bone mineralization. In a double-blind study, we have had the ...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元:
https://doi.org/10.1016/s8756-3282(96)00368-7
データ提供:米国国立医学図書館(NLM)
Etidronate and Tiludronate: A Comparative Study in Paget's Disease of Bone
Paget's disease of bone is a chronic condition characterized by excessive bone turnover. Bisphosphonates are a class of drugs used to treat this disease by inhibiting bone resorption. This study aimed to compare the effects of two bisphosphonates, etidronate and tiludronate, on radiological changes in patients with Paget's disease of bone.
The double-blind study involved 12 patients who received either etidronate or tiludronate at a fixed dose of 400 mg/day orally. The researchers monitored radiological changes in the patients' bones. The study found that tiludronate led to a more favorable bone balance compared to etidronate. This finding suggests that tiludronate may be a more effective bisphosphonate for treating Paget's disease of bone, potentially leading to better bone density and reducing the risk of fractures.
Tiludronate: A Potential Advantage in Treating Paget's Disease
The study's findings suggest that tiludronate may be more effective than etidronate in treating Paget's disease of bone. This is important because it provides physicians with a potentially better treatment option for patients with this disease. The study's results warrant further investigation into the long-term effects of both etidronate and tiludronate on bone health in patients with Paget's disease.
Living with Paget's Disease: A Focus on Bone Health
Paget's disease can significantly impact bone health and quality of life. This study highlights the importance of working closely with your doctor to manage this condition. It is crucial to discuss your treatment options and monitor your bone health regularly to ensure optimal outcomes.
Dr.Camel's Conclusion
This research is like a desert expedition, carefully comparing two different paths leading to the same destination: healthy bones. Tiludronate emerges as a promising route, potentially offering a smoother and more effective journey. Remember, seeking expert guidance is essential for navigating the complexities of this condition.
Date :
- Date Completed 1997-05-28
- Date Revised 2019-09-05
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.